B. Gobin

BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

D. Heymann, B. Ory, F. Blanchard, 2015, International journal of cancer.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.

D. Heymann, B. Ory, F. Redini, 2014, Cancer letters.

Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid.

A. Berdal, Yongwon Choi, D. Heymann, 2015, Bone.

Orthopaedic implant failure: aseptic implant loosening--the contribution and future challenges of mouse models in translational research.

P. Layrolle, D. Heymann, P. Rosset, 2014, Clinical science.

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Frederic Blanchard, G. Moriceau, D. Heymann, 2014, PloS one.

mAbs targeting RANKL in bone metastasis treatment

M. Heymann, F. Uckun, B. Isidor, 2013 .

Therapeutic approach of primary bone tumours by bisphosphonates.

G. Moriceau, F. Verrecchia, D. Heymann, 2010, Current pharmaceutical design.